2024-516783-29-00招募中4 期
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 340
- 试验地点
- 21
- 主要终点
- The primary criterion for judgment will be the rate of severe exacerbation during one year in patients on omalizumab vs mepolizumab, in the overall population. An additional primary criterion will be the rate of response to omalizumab vs that for mepolizumab, in the overall and stratified population(s).
研究概览
简要总结
To compare the rate and magnitude of response to omalizumab and mepolizumab in patients with severe allergic and eosinophilic asthma, in terms of annual rate of severe exacerbations (primary outcome).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form (ICF)
- •Age >18+ years (18-90 years old) at time of signing ICF
- •Able to comply with the study protocol, in the investigator’s judgment
- •Documented physician-diagnosed asthma
- •Eligible to omalizumab and mepolizumab and who have not yet received any of these therapies
排除标准
- •History of evidence of drug/substance abuse that would pose a risk to patient safety, interfere with the conduct of study, have an impact on the study results, or affect the patient’s ability to participate in the study, in the opinion of the investigator
- •Difficult to treat asthma and others severe respiratory diseases
- •Patient already currently/actively enrolled in a clinical therapeutic trial (testing another drug); the concomitant inclusion in a Registry, which may include biosampling, is not an exclusion criterion
- •Protected subjects (sous tutelle or curatelle), patients who are unable to express their consent, subjects who are deprived of liberty, subjects who are hospitalized without consent, subjects who are admitted in a health-care or social institute with another aim than that of the research, inclusion in an emergency situation, patient who is subject to a court order
- •Pregnant, post-partum or lactating women
- •Known sensitivity to any of the active substances or their excipients to be administered during the study
- •Active malignancy or malignancy in remission over less than 5 years
- •Patient not affiliated to a health insurance plan (FR)
结局指标
主要结局
The primary criterion for judgment will be the rate of severe exacerbation during one year in patients on omalizumab vs mepolizumab, in the overall population. An additional primary criterion will be the rate of response to omalizumab vs that for mepolizumab, in the overall and stratified population(s).
The primary criterion for judgment will be the rate of severe exacerbation during one year in patients on omalizumab vs mepolizumab, in the overall population. An additional primary criterion will be the rate of response to omalizumab vs that for mepolizumab, in the overall and stratified population(s).
次要结局
- Clinical features and biomarkers (or array signatures) analyzed in blood, mucosal and urine samples will be tested for their putative ability to predict a better response to oma- or mepolizumab (theranostic value). The candidate features are age at (severe) disease onset and presence of nasal polyps or aspirin hypersensitivity as well as serum specific/total IgE ratio and blood eosinophil levels.
- Asthma-related outcomes other than exacerbations – i.e. disease control reflected by ACT and ACQ6, asthma-related quality of life questionnaire reflected by AQLQ, lung function reflected by FEV1 % predicted and absolute change - as well as nasal symptoms (VAS and, for nasal polyps, endoscopic scoring) will be assessed in the oma- and mepolizumab groups, in the overall and stratified populations.
研究者
Charles Pilette
Scientific
Cliniques Universitaires Saint-Luc
研究点 (21)
Loading locations...
相似试验
进行中（未招募）
1 期
Predictive factors of response to omalizumab and mepolizumab in asthma.Adult patients (18-90 years old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).EUCTR2017-002473-19-FRCliniques Universitaires Saint-Luc364
已完成
不适用
Exploration of Predictive factors for response to Enzaltamide in bone metastasis of Prostate cancerBone metastasis of prostate cancerJPRN-UMIN000018634Department of Urology, Juntendo University Graduate School of Medicine100
招募中
不适用
Research to identify factors that predict response to enzalutamide using biopsy tissues from castration-resistant prostate cancer.castration resistant prostate cancerprostate cancer, castration-resistant, enzalutamideD064129JPRN-jRCTs051180140Akamatsu Shusuke340
已完成
不适用
A Study on Predictors of Treatment Response to ombitasvir/paritaprevir/r combination therapy in Patients with genotype 1 Chronic Hepatitis C Virus InfectioPatients with genotype 1 HCV infectionJPRN-UMIN000020299Hokkaido University260
尚未招募
4 期
Comparing efficacy of oral immunosuppressants in patients with moderate to severe psoriasisCTRI/2024/05/068034Surbhi Jain Self